Antikor Biopharma

Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours.

The company's proprietary platform uses smaller antibody fragments rather than whole antibodies to achieve improved tumour penetration and faster systemic clearance compared to conventional antibody-drug conjugates.

Antikor's lead programme targets cMET-expressing solid tumours and has demonstrated efficacy and safety data in advanced pre-clinical models.